Health
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society’s Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide – Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of…
Height Gain is Maintained in 2nd Year of Treatment
SAN RAFAEL, Calif., March 20, 2021 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that data from the open-label long-term extension of the Phase 3 study of 15 µg/kg dose of vosoritide was presented at an oral presentation at ENDO21, the Endocrine Society’s Annual Meeting by Professor Ravi Savarirayan, M.B., B.S., M.D., clinical investigator from the Murdoch Children’s Research Institute, Royal Children’s Hospital, University…
-
Business23 hours agoWhy this fantastic blue chip ASX 200 share could rise 20%
-
General22 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General16 hours agoPhotographers reveal iconic image of Gough Whitlam and Vincent Lingiari was posed on Wave Hill Walk-Off anniversary
-
Noosa News14 hours agoDog daycare program a TikTok hit for helping disabled find work, friends